Hey there, it’s Vadim 👋

It’s August, which means it’s a good time to finally go through the mail 😄

When each of you joined Bio Founder GPS, I asked what you’re working through and what would make the newsletter more useful.

Close to 400 of you took time to answer (thank you!), so I spent this weekend going through all the responses in detail.

A few questions came up again and again, so I thought I’d dedicate an issue to addressing them head-on.

🧭 HERE’S WHAT WE’LL COVER:

  • How do I get warm introductions to investors?

  • How do I know which investors actually lead rounds?

  • What do I do when investors say I’m “too early”?

  • Are angel investors worth pursuing?

  • Can I raise without an AI angle?

  • And more!

Let’s get into it! 🙂

But first: help me shape Bio Founder GPS this fall

The Bio Founder GPS world is growing, and I have a few exciting additions planned for the next few months.

As I think about what comes next, I want to make sure I’m spending my time on the things that bring you the most value.

So I have two quick questions for you:

Have something more specific in mind? Just reply to this email and let me know!

Thank you for helping Bio Founder GPS get to where it is today, and for shaping what comes next, I’m truly grateful!

📍 In NYC this month?

Two reasons to close your laptop and meet some amazing people:

Biotech Happy Hour with 2048 Ventures × Rho
Wednesday, August 5 | 5:30–7:30 PM
Mid-summer drinks, good company, and no agenda. Hosted at Brown Rudnick. [RSVP]

The Overlap [vol. 1]
Thursday, August 13 | 6:00–9:00 PM | Brooklyn
A small gathering of founders, operators, investors, creators, and life science people. No panels, no forced networking, just good conversations. [Request to join]

Going to either? Hit reply and let me know!

LETTER #1

“How do I get warm intros to investors?”

This was one of the most common challenges called out in your survey responses - by far.

My take: Warm introductions are less about having the perfect network and more about building one habit into every conversation.

Whether you’re speaking with a founder, your CRO account manager, an advisor, or an investor who has just passed, end with some version of:

“Based on what you’ve heard, is there anyone you think I should speak with?”

That wording matters - not everyone may have a rolodex of investors. But asking who you should speak with gives them something more specific to react to, based on what they just learned about your company.

Now, I get it - this may sound obvious, and hardly like a meaningful fundraising tactic, but you’d be surprised by how quickly this compounds. Make it a genuine habit, and before long your main challenge will go from finding people to speak with to protecting your calendar and being more deliberate about which conversations are actually worth your time - including investors.

With that in mind, here are a few more ideas for getting warm intros:

Start with your current investors

Investors invest together. If you've raised anything at all, your existing backers have a list of people they co-invest with regularly. That's the shortest path you have and most founders never fully interrogate it.

Work the portfolio, not the partner

This is something very few founders do, especially in biotech.

First, identify your target funds. Then, look at companies those funds backed at any point - even a few years ago. Make a list of the founders of those companies, and reach out directly as a peer - founder to founder. If there's any way you can help them, lead with that. Then be candid: you're raising, and you think the fund that backed them could be a fit.

One important thing here: DON’T ask for a warm intro from someone you've never met. Instead, ask if they'd be open to a short call about their experience with the fund. That's a reasonable ask between founders, and the intro often follows on its own.

Every pass is a referral opportunity

Founders often miss this moment because they are still trying to change the investor’s mind, or simply feel awkward asking for help after a rejection. But many investors are happy to point you toward firms with a different mandate, and they are often well placed to do it: they’ve just spent time understanding your company and already have a network of other investors they can build from.

Two more areas founders often overlook

Your law firm, particularly if it works with startups and venture financings, may be able to make relevant introductions. And associates, principals, and EIRs at a fund are often easier to reach than partners. In many firms, sourcing new opportunities is a significant part of their role.

What I'd do next: Pick your ten highest-priority funds. For each one, identify a portfolio founder you could reasonably approach for a conversation. You may be surprised by how much outreach your current network can already support.

LETTER #2

“How do I know which investors actually lead rounds?”

My take: Pay attention to what a fund has done recently, not what is said on industry panels or social media.

You can read the website, you can listen to partners and portfolio founders on podcasts, X, and LinkedIn - all of that gives you useful context.

But the proof will always be in the pudding - where they actually deployed capital over the past 24-36 months.

I’d start with two questions:

How many new investments did the fund make?

And how often did it lead or co-lead those rounds?

Then I’d go one level deeper:

  • At what stages did it invest?

  • How large were the rounds?

  • Were its checks large enough to support a lead position?

  • Has it recently led a round for a company that looks anything like yours?

  • Does the firm lead consistently, or only under specific circumstances?

A fund that participated in twelve financings but led only two may still lead the right opportunity. But it probably should not be treated as a reliable lead candidate without more evidence.

Recent behavior matters because firms change. Partners leave, new funds are raised, and ownership targets shift. A firm that regularly led Seed rounds five years ago may now be concentrating on Series A and B investments.

You can piece this together through company financing announcements, portfolio pages, LinkedIn, Crunchbase, PitchBook, and similar databases.

You can also use an LLM to help organize the research, but give it sources and verify the underlying transactions. Models are very good at turning incomplete information into a confident conclusion, so always check their work.

And when you speak with the investor, ask directly:

“For companies at our stage, does your firm typically lead and price rounds, co-lead, or participate alongside another lead?”

That’s a normal diligence question for a founder to ask.

What I’d do next: Run this analysis on the ten investors currently at the top of your list. The goal is not to make the list longer, but to separate plausible leads from funds that are more likely to follow.

Small aside: I’m also working on something that should make this kind of research much easier. Stay tuned 👀

LETTER #3

“Investors say I’m too early. But I need capital to reach the milestone they want.”

This is probably the number one Catch-22 in our field, and a topic we can dedicate a whole book to.

The fact that the goal posts keep moving, and investors keep requiring more “de-risking”, all the while non-dilutive sources are uncertain at best - does not make this at all easier.

My take: Rather than trying to finance the entire journey, identify the next proof point that could materially change the fundraising conversation. Then match the source and structure of capital to that main proof point.

A few options to consider:

Explore milestone-based tranching

In some cases, a round can be structured so portions of the capital are released after clearly defined technical, regulatory, or commercial milestones - just like they would be under a “biobucks” deal with pharma.

That can make the initial commitment more manageable for an investor, but it also introduces risk for the company. The milestone needs to be objective, within your control, and tied to enough capital for you to reach it. A vague or poorly designed tranche can create a dispute precisely when you are most dependent on the next release.

Consider all non-dilutive options

Most life science founders know NIH, SBIR, and STTR. Fewer look systematically at programs such as NSF SBIR, BARDA, ARPA-H, or DoD CDMRP, which offer funding through a different process and review structure.

State and local programs also deserve attention. Depending on where your company is based, there may be economic-development grants, matching programs, translational awards, or tax incentives available through your state, city, or regional ecosystem.

Reduce the cost of the milestone itself

If the blocker is a six-figure instrument, financing the purchase may not be the only path.

Could you use a university core facility? Structure an academic collaboration? Rent time on the equipment? Outsource the experiment to a CRO? Partner with a group that already has the infrastructure?

Sometimes the fastest route is not raising more money but redesigning the work so the next proof point simply costs less.

Look at accelerators and translational programs

Programs such as SOSV IndieBio, ACS BrightEdge, Nucleate, university proof-of-concept funds, disease foundations, and selected strategic partnerships can sometimes help companies cross the gap between promising science and an institutional financing.

The terms, check sizes, and fit vary widely, so treat them as distinct capital sources rather than interchangeable programs.

That all being said, here is one move most founders still overlook:

Ask the investor directly what they would need to see to commit.

Is it specific data? A specific team hire? Customer traction? A regulatory interaction? A signed partner?

Ask:

“What would need to be true for this to become investable for you?”

Or:

“If we came back in six to twelve months, what would you need to see to be excited to re-engage?”

Their answer may reveal that the gap is specific and bridgeable. It may also reveal that “too early” was simply a polite pass.

Either way, you now have more useful information.

And when the investor is genuinely interested but you’re truly early for their mandate, you have the beginnings of a warm lead for the next round. Few things build more credibility than listening carefully, executing against the signal, and returning months later having done what you said you would do.

What I’d do next: Ask that question in your next three investor conversations and then compare the answers. If multiple investors independently point to the same missing proof point, pay attention.

LETTER #4

“Are angel investors worth pursuing for a biotech round?”

I’m aware I may ruffle some feathers with this one 🙂

First, let’s define what I mean by an angel.

For this discussion, I’m referring to someone writing a check below $100K and more typically between $10K and $50K.

Individuals who can comfortably write $250K or $500K and up, I bucket with family offices - even when that's not what they call themselves.

My take: Whether angels are worth pursuing depends heavily on the size of your round and what the investor brings besides capital.

On the one hand, there could be real advantages.

Angels do not have an investment committee, so they can theoretically move quickly. The right person may also bring industry relationships, operating experience, domain credibility, or access to future investors and partners.

But the process is not always as simple as it sounds

Some angels may end up moving a lot slower than professional investors.

Even if they come from a healthcare or pharma background, they may have very limited experience with early-stage startups and biotech, and may not fully appreciate the timelines, technical risks, capital requirements, or likelihood that the company will need several more rounds before reaching an exit.

Expectations can also become misaligned. You may encounter someone who assumes Big Pharma will acquire the company next year for billions, or who requires weeks of education and negotiation for a relatively small check.

That does not make angels bad investors, but it does mean that you need to consider the value of the relationship alongside the time required to secure and manage it.

Here is how I would evaluate an angel

What do they bring besides the check? Could they become a credible advisor? Do they understand your category? Can they help with development, regulatory strategy, commercialization, hiring, or company building?

Who can they help you reach? Do they have relationships with VCs, family offices, pharma companies, future customers, partners, or team members?

Does the check make sense relative to the round? If you are raising a $500,000 friends-and-family round or pre-seed extension, $25,000 and $50,000 checks can be meaningful. Angels and angel groups may be a very reasonable part of the strategy.

But if you’re raising $2M to $5M, filling the round one small check at a time can consume an enormous amount of founder attention. In that context, an angel may need to bring substantial value beyond the money to justify the effort.

Will they be constructive on the cap table? You want investors whose expectations match the reality of building a life sciences company, and who will remain helpful when the path takes longer than anyone hoped.

What I’d do next: For every angel currently in your pipeline, write one sentence describing what they could contribute beyond the capital. If that sentence is difficult to complete, think carefully about how much time the conversation deserves.

LETTER #5

“How can we raise funding if we’re not an AI company?”

In 2026, it can definitely feel like AI has sucked all the air out of a room that was already getting pretty thin after 2021. Family offices, VCs, and angels all seem bent on finding the next AI unicorn.

And if you actually are using AI, there’s a second problem: how do you show it without getting over your skis, or getting valued as a service provider rather than as a biotech company building proprietary assets?

My take: Yes, you can raise without it, but don’t try to win arguments about why AI is priced the way it is. Instead, focus your energy on finding the capital that was never pointed at AI companies in the first place.

Here’s what I mean:

A fund that raised a dedicated life sciences vehicle has a mandate. There’s usually more flexibility in those documents than founders assume, but there’s still a boundary, and it doesn’t move just because a different category got hot.

For example - Curie.Bio closed a $340 million Seed Fund II in January 2025, after backing 26 companies, with a target of up to 25 new investments during 2026. Its seed strategy is built around therapeutics programs reaching milestones such as in vivo proof-of-concept or development candidate selection. The fund is open to a wide range of technologies and modalities, but the investment still has to result in a therapeutics company.

Disease foundation capital follows the same basic logic. The Cystic Fibrosis Foundation may fund computational work that advances cystic fibrosis research, but it’s not looking for a general-purpose AI infrastructure company. That is not what the capital exists to support.

So the question usually isn’t so much whether you can win attention against AI companies, but whether the investors on your list were ever going to fund you at all.

Now, if AI is legitimately part of your story, the challenge is different: you need to show exactly what it does and why it matters.

“We used machine learning to identify three previously overlooked targets, two of which were validated in vivo” is a claim someone can diligence.

“AI-powered discovery platform” doesn’t describe your company. It describes a category, and a very broad one at that.

If AI is part of your story, be precise about where the value sits. Are you using it to create proprietary assets, data, or products that you own, or are you primarily selling analysis and custom work to clients? Investors will evaluate those models differently, so make sure the deck reflects the business you are actually building.

What I’d do next: Here again, the proof is in the pudding. Once you gather your initial list of potential funds, look at their most recent deals, ideally from the past six to twelve months.

Is the fund staying consistent with its historical focus? Or does the portfolio suggest it’s becoming more generalist and moving away from its former center of gravity? Take a data-driven approach, and prioritize your efforts accordingly.

THAT’S A WRAP

That was fun 🙂

I really enjoyed going back through your responses and pulling this mailbag together.

My goal with Bio Founder GPS has always been to build something by bio founders, for bio founders. The questions you send in help shape what I write here, what resources I build, and even what I ask guests on the Bio Founder GPS podcast.

So if there’s a fundraising question, company-building challenge, or investor conversation keeping you up at night, just reply to this email and tell me.

Chances are, you’re not the only founder thinking about it.

Until next week!

- Vadim

When you’re ready, here’s how I can help:

Pitch Deck Audit - a second pair of eyes on your deck before you get in front of investors. I'll go through it the way an investor would and tell you what's landing, what isn't, and what questions you'll get asked. You get slide-by-slide feedback, a custom list of investors, and we spend an hour going through everything live.

Book a strategy call - sometimes it just helps to think out loud with someone who's been on the other side of the table. If that sounds useful, fill out the form below and let’s chat!